Patent EP0387701B1 successfully refreshed from Google Patents.
EP0387701B1
Expired / Lapsed
EP
⏱️ 0.0 years remaining
Use of intercellular adhesion molecules, and their binding ligands in the treatment of asthma
Assignee: Boehringer Ingelheim Pharmaceuticals Inc
•
Filing: 1990-03-08
•
Granted: 1992-08-12
•
Expires: 2010-03-08
Abstract
Abstract The present invention relates to the use of intercellular adhesion molecules (ICAM-1), their functional derivatives, and molecules which bind to them, in the treatment of asthma.
Inventors
- 👤 Craig D. Wegner
- 👤 Robert H. Gundel
- 👤 Robert Rothlein
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-11-01 21:36
CPC Classifications
C; C07; C07K; C07K14/00; C07K14/435; C07K14/705; C07K14/70503; C07K14/70525; A; A61; A61P; A61P11/00; A61P11/06; A61P11/08; C07K14/70546; C07K14/70553; C07K16/00; C07K16/18; C07K16/28; C07K16/2803; C07K16/2821; C07K16/2839; C07K16/2845; A61K; A61K38/00
Claims Analysis
Total Claims: 21
Claim 1
Independent Claim
120 words
The use of an agent selected from (a) an antibody capable of binding to ICAM-1; (b) a fragment of said antibody (a), said fragment being capable of binding to ICAM-1; (c) ICAM-1, being substantially free of natural contaminants; (d) a functional derivative of ICAM-1; (e) an antibody capable of binding to a member of the CD18 family of glycoproteins; (f) a fragment of said antibody (e), said fragment being capable of binding to a member of the CD18 family of glycoproteins; (g) a member of the CD18 family of glycoproteins, being substantially free of natural contaminants; and (h) a functional derivative of a member of the CD18 family of glycoproteins. in the manufacture of a pharmaceutical preparation for treating asthma.
Claim 2
Dependent Claim
120 words
The use of an agent selected from (a) an antibody capable of binding to ICAM-1; (b) a fragment of said antibody (a), said fragment being capable of binding to ICAM-1; (c) ICAM-1, being substantially free of natural contaminants; (d) a functional derivative of ICAM-1; (e) an antibody capable of binding to a member of the CD18 family of glycoproteins; (f) a fragment of said antibody (e), said fragment being capable of binding to a member of the CD18 family of glycoproteins; (g) a member of the CD18 family of glycoproteins, being substantially free of natural contaminants; and (h) a functional derivative of a member of the CD18 family of glycoproteins. in the manufacture of a pharmaceutical preparation for treating asthma.
Claim 3
Dependent Claim
32 words
The use of claim 1 wherein said agent is said antibody (a) capable of binding to ICAM-1, or a fragment of said antibody (a), said fragment being capable of binding to ICAM-1.
Claim 4
Dependent Claim
13 words
The use of claim 2 wherein said antibody (a) is a monoclonal antibody.
Claim 5
Dependent Claim
14 words
The use of claim 3 wherein said monoclonal antibody is the monoclonal antibody R6.5.
Claim 6
Dependent Claim
16 words
The use of claim 1 wherein said agent is ICAM-1, being substantially free of natural contaminants.
Claim 7
Dependent Claim
14 words
The use of claim 1 wherein said agent is a functional derivative of ICAM-1.
Claim 8
Dependent Claim
14 words
The use of claim 6 in which the functional derivative contains ICAM-1 domain 1.
Claim 9
Dependent Claim
14 words
The use of claim 6 in which the functional derivative contains ICAM-1 domain 2.
Claim 10
Dependent Claim
16 words
The use of claim 6 in which the functional derivative is a soluble derivative of ICAM-1.
Claim 11
Dependent Claim
46 words
The use of claim 1 wherein said agent is said antibody (e) capable of binding to a member of the CD18 family of glycoproteins; or a fragment of said antibody (e), said fragment being capable of binding to a member of the CD18 family of glycoproteins.
Claim 12
Dependent Claim
26 words
The use of claim 10 wherein said antibody (e) is able to bind to an alpha subunit of said member of the CD18 family of glycoproteins.
Claim 13
Dependent Claim
26 words
The use of claim 10 wherein said antibody (e) is able to bind to a beta subunit of said member of the CD18 family of glycoproteins.
Claim 14
Dependent Claim
23 words
The use of claim 1 wherein said agent is a member of the CD18 family of glycoproteins, being substantially free of natural contaminants.
Claim 15
Dependent Claim
27 words
The use of claim 13 wherein said member of the CD18 family of glycoproteins contains an alpha subunit of a member of the CD18 family of glycoproteins.
Claim 16
Dependent Claim
27 words
The use of claim 13 wherein said member of the CD18 family of glycoproteins contains a beta subunit of a member of the CD18 family of glycoproteins.
Claim 17
Dependent Claim
34 words
The use of claim 13 wherein said member of the CD18 family of glycoproteins is a heterodimer containing both an alpha and a beta subunit of a member of the CD18 family of glycoproteins.
Claim 18
Dependent Claim
21 words
The use of claim 13 wherein said agent is a functional derivative of a member of the CD18 family of glycoproteins.
Claim 19
Independent Claim
41 words
A method of identifying an agent capable of therapeutic potential in the treatment of asthma which comprises administering said agent to a non-human mammal having received multiple inhalations of an antigen, and measuring any increase in airway responsiveness of said mammal.
Claim 20
Independent Claim
41 words
A method of identifying an agent capable of therapeutic potential in the treatment of asthma which comprises administering said agent to a non-human mammal having received multiple inhalations of an antigen, and measuring any increase in airway responsiveness of said mammal.
Claim 21
Dependent Claim
20 words
The method of claim 18 wherein any increase in airway responsiveness in said mammal is measured with methacholine or histamine.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.